Decision: Favourable

Study Title:

A Phase 2b Randomized, Double-blind, Active- and Placebocontrolled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn’s Disease

  • NREC Code:


  • Decision:


  • Meeting Date:


  • Study Type:

    CT application

  • Principal Investigator:

    Professor Laurence Egan

  • PI Institution:

    University Hospital Galway

  • Sponsor:

    Janssen-Cilag International NV

Scroll to Top